Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Nice issues draft anaphylaxis guidelines

Nice has recommended that all patients who have had a suspected anaphylactic episode should be given an adrenaline injector as an interim measure in draft guidelines published today.

Circumstances of the onset of an anaphylactic episode should also be immediately recorded to help identify any possible triggers, Nice recommended.

All children given treatment for anaphylaxis should be admitted to hospital and placed under the care of a paediatric specialist team. The document urged primary care organisations and hospitals to organise referral pathways for patients who received emergency treatment for anaphylactic episodes.

The draft guidelines have been created after a drastic rise in anaphylactic episodes over the past 14 years, according to Nice. Nice hopes to standardise treatment of patients who have had anaphylactic episodes through the distribution of the guide.

Topics

         
Registrant member of the Assurance and Appointments Committee 
Nationwide
£ Renumeration

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD014263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel